FOLFOX4与XELOX治疗晚期大肠癌(3)
 |
| 第1页 |
参见附件。
[4] Saif MW. Capecitabine and hand-foot syndrome [J]. Expert Opin Drug Saf，2011，10(2)：159-169.
[5] 孙燕.内科肿瘤学[M].北京：人民卫生出版社，2001：90.
[6] De Gramont A，Tournigand C，André T，et al. Targeted agents for adjuvant therapy of colon cancer [J]. Semin Oncol，2006，33(6 Suppl 11)：42-45.
[7] Simpson D，Dunn C，Curran M，et al. Oxaliplatin：a review of its use in combination therapy for advanced metastatic colorectal cancer [J]. Drugs，2003，63(19)：2127-2156.
[8] Failli A，Consolini R，Legitimo A，et al. Evaluation of in vitro cytotoxicity of oxaliplatin and 5-fluorouracil in human colon cancer cell lines：combination versus sequential exposure [J]. J Biol Regul Homeost Agents，2011，25(4)：575-588.
[9] Landherr L，Nagykálnai T. The development of the first line treatment of metastatic colorectal cancer(mCRC)[J]. Magy Onkol，2009，53(3)：237-246.
[10] Hameed H，Cassidy J. Use of capecitabine in management of early colon cancer [J]. Cancer Manag Res，2011，3：295-299.
[11] Zhao L，Bai C，Shao Y，et al. A phase Ⅱ study of neo adjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer [J]. Cancer Lett，2011，310(2)：134-139.
[12] Walko CM，Lindley C. Capecitabine：a review [J]. Clin Ther，2005，27(1)：23-44.
(收稿日期：2012-10-08 本文编辑：张瑜杰)
您现在查看是摘要介绍页，详见PDF附件(3092kb)。